NCT07137481View on ClinicalTrials.gov

Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

February 28, 2026

Primary Completion Date

July 31, 2030

Study Completion Date

July 31, 2032

Conditions
Hematological Malignancies
Interventions
DRUG

C9/CD5CAR/IL-15 NK cells

Given PO or IV

DRUG

Rituximab

Given by IV

DRUG

Fludarabine

Given by IV

DRUG

Cyclophosphamide

Given by IV

Trial Locations (1)

77030

The University of Texas M. D. Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER